Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on November 5, 2013, primarily to announce its financial and operating results for the third quarter ended September 30, 2013. The press release detailing these results is furnished as an exhibit to this filing. While the 8-K itself does not contain the detailed financial figures, it serves as the official notification mechanism for investors to access the company's latest performance metrics, revenue generation, and operational updates for the period. Investors should refer to the furnished press release (Exhibit 99.1) for comprehensive information regarding the company's financial condition and operational performance during the third quarter of 2013. The filing explicitly states that the information furnished is not considered "filed" for certain regulatory purposes, underscoring the importance of the press release itself for detailed analysis.
Key Highlights
- 1Regeneron Pharmaceuticals announced its third quarter 2013 financial and operating results.
- 2The official results were released via a press release dated November 5, 2013.
- 3The press release is furnished as Exhibit 99.1 to the 8-K filing.
- 4Investors are directed to Exhibit 99.1 for detailed financial and operational performance data for Q3 2013.
- 5The filing serves as a notification mechanism for the release of quarterly earnings.
- 6Information furnished in this Item 2.02 is not deemed 'filed' under Section 18 of the Exchange Act.